BioSpace News Archive

KORU Medical Systems, Inc., a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce a clinical supply agreement for a novel subcutaneous immunoglobulin drug entering Phase 3 trials.

VedaBio today announced that Frédéric Sweeney, PhD, has been appointed President and Chief Executive Officer. He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio.

Biogen Inc. announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy who have unmet clinical needs after treatment with Zolgensma®.

Rezolute, Inc. announced results from a preclinical pharmacology study that validate the potential for its lead clinical compound, RZ358, to treat individuals with non-islet cell tumors that have uncontrolled hypoglycemia.

BiomX Inc. today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”).

Agenus Inc. today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting.

Fusion Pharmaceuticals Inc. today announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 245,300 shares.

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure, announced positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Muse Microscopy, Inc., a wholly-owned subsidiary of Smart Health Diagnostics Company, is developing a slide-free diagnostic imaging platform designed to transform the patient’s experience by providing the ability to generate digital tissue images within minutes to send to the pathologist for an immediate read.

Spero Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results.